Clinical Trial Update: Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta

View source ↗

Summary

The completed trial evaluated immune responses in Fabry disease patients who switched from agalsidase alfa to agalsidase beta.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• ELELYSO (TALIGLUCERASE ALFA)
• FABRAZYME (Agalsidase beta)

Snippet

Sponsor: O & O Alpan LLC | Conditions: Fabry Disease | Status: COMPLETED